Sofosbuvir–velpatasvir for treatment of chronic hepatitis C virus infection in Asia: a single-arm, open-label, phase 3 trial
The Lancet. Gastroenterology & hepatology2018Vol. 4(2), pp. 127–134
Citations Over TimeTop 10% of 2018 papers
Lai Wei, Seng Gee Lim, Qing Xie, Kính Nguyen Văn, Teerha Piratvisuth, Yan Huang, Shanming Wu, Ming Xu, Hong Tang, Jun Cheng, Hùng Lê Mạnh, Yanhang Gao, Zhuangbo Mou, Abhasnee Sobhonslidsuk, Xiaguang Dou, Satawat Thongsawat, Yuemin Nan, Chee‐Kiat Tan, Qin Ning, Hoi Poh Tee, Yimin Mao, Luisa M. Stamm, Sophia Lu, Hadas Dvory‐Sobol, Hongmei Mo, Diana M. Brainard, Yongfeng Yang, Long Van Dao, Guiqiang Wang, Tawesak Tanwandee, Peng Hu, Pisit Tangkijvanich, Lunli Zhang, Zhi Gao, Feng Lin, Thi Tuyet Phuong Le, Jia Shang, Guozhong Gong, Jun Li, Minghua Su, Zhongping Duan, Rosmawati Mohamed, Jin Hou, Jidong Jia
Related Papers
- → Comparing the risk of hypothyroidism in HCV patients treated with different DAA drugs combinations (sofosbuvir + interferon + ribavirin and sofosbuvir + daclatasvir + ribavirin)(2020)5 cited
- → 751 Patient-Reported Outcomes in Chronic Hepatitis C Patients With Cirrhosis Treated With Ribavirin-Containing Regimens: Sofosbuvir/Velpatasvir and Ribavirin or Sofosbuvir and Ribavirin(2016)
- → TREATMENT OF CHRONIC HEPATITIS C GENOTYPE 6 PATIENT WITH TRIPLE THERAPY PEG-IFN, RIBAVIRIN AND SOFOSBUVIR: CASE REPORT AND REVIEW OF LITERATURE(2017)
- PE-074 : Efficacy and Safety of Sofosbuvir and Ribavirin in Treatment of HCV Genotype 2(2017)
- → Efficacy of Sofosbuvir Plus Ribavirin with and without Pegylated Interferon-Α in Patients with HCV Genotype 3A Infection(2021)